Moreno Evelyn V Sells 8,165 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Moreno Evelyn V cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 38.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,860 shares of the medical research company’s stock after selling 8,165 shares during the period. IQVIA makes up approximately 1.4% of Moreno Evelyn V’s holdings, making the stock its 19th biggest position. Moreno Evelyn V’s holdings in IQVIA were worth $2,976,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of IQV. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in shares of IQVIA by 36.7% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 1,908 shares of the medical research company’s stock worth $441,000 after acquiring an additional 512 shares during the period. Enterprise Financial Services Corp lifted its holdings in shares of IQVIA by 29.9% during the 4th quarter. Enterprise Financial Services Corp now owns 1,646 shares of the medical research company’s stock worth $381,000 after acquiring an additional 379 shares during the period. Central Valley Advisors LLC bought a new position in shares of IQVIA during the 4th quarter worth about $1,186,000. Dai ichi Life Insurance Company Ltd lifted its holdings in shares of IQVIA by 30.2% during the 4th quarter. Dai ichi Life Insurance Company Ltd now owns 24,157 shares of the medical research company’s stock worth $5,589,000 after acquiring an additional 5,609 shares during the period. Finally, Nemes Rush Group LLC increased its position in shares of IQVIA by 4.0% during the 4th quarter. Nemes Rush Group LLC now owns 24,404 shares of the medical research company’s stock worth $5,647,000 after purchasing an additional 938 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Activity

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

IQV has been the subject of several research reports. BTIG Research initiated coverage on shares of IQVIA in a research report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective for the company. Truist Financial lowered their price objective on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. SVB Leerink initiated coverage on shares of IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective for the company. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Finally, Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $257.57.

IQVIA Price Performance

IQV traded up $2.59 on Thursday, hitting $228.62. 271,155 shares of the stock were exchanged, compared to its average volume of 952,191. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The business has a 50-day moving average of $238.14 and a two-hundred day moving average of $228.32. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The firm has a market capitalization of $41.65 billion, a price-to-earnings ratio of 30.87, a PEG ratio of 2.09 and a beta of 1.52.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.